Novocure today announced CEO Asaf Danzinger will resign from his position, effective January 1, 2025.
Danzinger has accepted a new role as senior advisor at the cancer treatment tech company, effective on the same date until early 2026. He has served as Novocure’s CEO since 2002.
“It has been a special honor and one of the greatest privileges of my life to serve as Novocure’s CEO for the last 22 years,” said Danziger. “I am very proud of the organization we have built starting with just a few people in a preclinical lab to where we stand today – treating thousands of patients living with aggressive forms of cancer. Now, we are poised to expand the potential of Tumor Treating Fields therapy to many more people. I am confident that under Ashley’s leadership Novocure is well positioned to achieve great things.”
Novocure has promoted CFO Ashley Cordova to lead the company, effective January 1, 2025.
“Under Asaf’s leadership, Novocure has grown from its earliest days as a start-up into the successful, global company we see today. Our patient-forward mission is a manifestation of Asaf’s vision,” said executive chair William Doyle. “On behalf of Novocure’s Board of Directors, we are grateful for all of Asaf’s many accomplishments and are excited to welcome Ashley as our next CEO. Ashley’s strategic vision, commitment to our mission, and proven track record of operational excellence position her perfectly to drive Novocure’s next stage of growth.”
Cordova will remain as CFO until a replacement is appointed. She has served as the company’s CFO since September 2020, joining the company in June 2014 as director of global treasury.
Since joining Novocure, Cordova has risen in the ranks and taken on varying roles of responsibility in the finance department, including senior director of investor relations, global treasurer, and vice president of finance and investor relations.
Before joining Novocure, Cordova held various financial roles at Zoetis and Pfizer.
“It has been a professional and personal highlight for me to work hand in hand with Asaf over the past 10 years and I am grateful for his leadership and partnership,” Cordova said. “Novocure’s mission to extend survival in aggressive forms of cancer is as significant today as it was 20 years ago, and I am excited to take on the role of CEO at this pivotal time as we look to expand the reach of Tumor Treating Fields therapy across multiple solid tumor indications.”
Chief operating officer Wilco Groenhuysen resigned and will officially leave his post on October 1, 2024. Mukund Paravasthu, currently senior VP of product development, will expand his current responsibility and transition into the chief operating officer role.
“I would like to personally thank Wilco for his friendship, dedication, and leadership over the last 12 years,” said Danziger. “Wilco helped shape and build our financial, back office and operations functions, and I am grateful for the enduring impact he made at Novocure.”
